Abstract
Current thrombolytic therapy consists of high dose tPA administered iv for 60-90 minutes. This treatment has had only limited success in acute myocardial infarction (AMI) [1-3], and consequently has more recently been replaced by percutaneous coronary intervention (PCI) as the treatment of choice in AMI [4]. Although PCI is time-consuming and delays coronary reperfusion, better clinical outcomes than with tPA were nevertheless obtained [5]. In the treatment of ischemic stroke, a tPA dose reduction was required due to a 20% intracranial hemorrhage (ICH) incidence when the AMI dose was used [6].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Online Journal of Cardiology Research & Reports
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
